BJDX Bluejay Diagnostics, Inc.

Price Chart

Executive Summary

Bluejay Diagnostics has entered into a securities purchase agreement to raise approximately $8.5 million through a private placement priced at $2.325 per share, coupled with Series G ($2.075 strike, 5-year term) and Series H ($2.075 strike, 2-year term) warrants exercisable for 100% coverage each. The company also issued a placement agent warrant with a $2.9063 strike. Proceeds are earmarked for working capital, and the transaction imposes a 90-day hard lock and a 12-month ban on variable-rate transactions. For a micro-cap with a ~$5M market cap, this is a highly dilutive capital raise that existing shareholders will absorb.

Key Financial Metrics

Actionable Insight

Key Facts

• Raised ~$8.5M through a PIPE at $2.325/share, a deep discount likely to the prevailing market price for a micro-cap.
• Purchasers received Series G (5-yr, $2.075 strike) and Series H (24-month, $2.075 strike) warrants for 100% of their share/pre-funded warrant allocation each – total potential dilution equals ~3x the base shares issued.
• Placement agent H.C. Wainwright received warrants at $2.9063 strike (5-yr term), adding further overhang.
• Registration rights agreement requires filing an S-3 resale registration within 15 days with a 45-day effectiveness target (75 days on full review), enabling near-term resale of the PIPE shares and warrant shares.
• 90-day lock-up on new equity issuances (except exempt grants) and 12-month ban on variable-rate transactions (equity lines/ATMs), precluding certain near-term capital alternatives.
• Proceeds stated for working capital use, with restrictions on debt repayment (excluding trade payables), stock redemption, litigation settlement, and FCPA/OFAC violations.
• Non-disclosure provisions for material, non-public information are effectively waived for purchasers post-disclosure.

Financial Impact

The offering represents ~170% of the pre-offering market cap. Total potential dilution from shares + all warrants could exceed 600% of pre-offering shares if fully exercised, drastically reducing per-share value for existing holders.

Risk Factors

• Massive dilution: ~3x base shares plus additional placement agent warrants could flood the float.
• Warrant exercise risk: $2.075 strike offers immediate intrinsic value (if current price > strike), incentivizing cashless or cash exercises, further diluting existing holders.
• Resale registration readies the PIPE shares for immediate sale into the market within weeks.
• Micro-cap volatility: a $5M market cap is highly susceptible to order flow from any selling by PIPE investors.
• Nasdaq compliance risk: the company may slip below minimum bid price or market value of listed securities post-dilution.

Market Snapshot

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

US Market Status